Key Insights

Highlights

Treatment Research

7 treatments under study, led by Glofitamab Gemcitabine And Oxaliplatin As Induction Therapy

Research Leaders

10 sponsors active, led by Austin Health

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Phase 2 (2)

Trial Status

Not Yet Recruiting2

Clinical Trials (2)

Showing 2 of 2 trials
NCT07634289Phase 2Not Yet RecruitingPrimary

Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT07542678Phase 2Not Yet RecruitingPrimary

Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell Lymphoma Patients Eligible for CAR-T-cell Therapy With a Glofitamab-based Induction and Consolidation Concept

Showing all 2 trials

Research Network

Common Treatments

  • Glofitamab Gemcitabine And Oxaliplatin As Induction Therapy1
  • 18fgranzyme B1
  • Glofitamab As Consolidation Therapy1
  • Obinutuzumab1
  • 89zrdfcrefmirlimab1

Active Sponsors

  • Austin Health1
  • Fiona Stanley Hospital1
  • Olivia Newton-John Cancer Research Institute1
  • Princess Alexandra Hospital, Brisbane, Australia1
  • Universitätsklinikum Düsseldorf, Germany1

Top Investigators

Related Conditions

  • Relapsedrefractory Large Bcell Lymphoma1

Activity Timeline